Michael Kauffman
Impact in
- Hematology top 0.5%
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Oncology top 1%
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis
Papers in
-
- Nuclear Structure and Function 110
- Protein Degradation and Inhibitors 23
- RNA Research and Splicing 15
- Ubiquitin and proteasome pathways 14
- Oncology 50
- Cancer-related Molecular Pathways 31
- Co-authors
- Julian Adams (2 shared papers)Sharon Shacham (155 shared papers)Thomas J. Kelly (4 shared papers)Yosef Landesman (59 shared papers)Dilara McCauley (45 shared papers)Asfar S. Azmi (18 shared papers)William Senapedis (34 shared papers)Amro Aboukameel (16 shared papers)
- Journals
- Blood (48 papers)Journal of Clinical Oncology (36 papers)Cancer Research (28 papers)Oncotarget (11 papers)Annals of Oncology (7 papers)
- Partner nations
- United StatesCanadaDenmark
In The Last Decade
Michael Kauffman
187 papers receiving 5.5k citations
Michael Kauffman's Hit Papers
Peers
Comparison fields: 5 of 110
- Hematology 1.6k
- Oncology 1.5k
- Molecular Biology 4.0k
- Genetics 399
- Cancer Research 325
Countries citing papers authored by Michael Kauffman
This map shows the geographic impact of Michael Kauffman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Kauffman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Kauffman more than expected).
Fields of papers citing papers by Michael Kauffman
This network shows the impact of papers produced by Michael Kauffman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Kauffman. The network helps show where Michael Kauffman may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Kauffman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 191 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Hit paper breakdown → | 2004 | 569 |
| 2 | Development of the Proteasome Inhibitor Velcade™ (Bortezomib) Hit paper breakdown → | 2004 | 540 |
| 3 | 2016 | 183 | |
| 4 | 2012 | 165 | |
| 5 | 2001 | 164 | |
| 6 | 2013 | 162 | |
| 7 | 2012 | 147 | |
| 8 | 2013 | 141 | |
| 9 | 2013 | 123 | |
| 10 | 2017 | 117 | |
| 11 | 1991 | 115 | |
| 12 | 1989 | 115 | |
| 13 | 2006 | 107 | |
| 14 | 2017 | 104 | |
| 15 | 2018 | 103 | |
| 16 | 2017 | 102 | |
| 17 | 2016 | 93 | |
| 18 | 2016 | 92 | |
| 19 | 2012 | 90 | |
| 20 | 2014 | 83 |
About Michael Kauffman
Michael Kauffman is a scholar working on Molecular Biology, Oncology, Hematology, Cancer Research and Genetics, having authored 191 papers that have together received 5.6k indexed citations. Recurring topics across this work include Nuclear Structure and Function (110 papers), Multiple Myeloma Research and Treatments (32 papers), Cancer-related Molecular Pathways (31 papers), Protein Degradation and Inhibitors (23 papers), Cancer, Lipids, and Metabolism (18 papers), Acute Myeloid Leukemia Research (16 papers), RNA Research and Splicing (15 papers) and Ubiquitin and proteasome pathways (14 papers). The work is most often cited by research in Hematology (1.6k citations), Oncology (1.5k citations), Molecular Biology (4.0k citations), Genetics (399 citations) and Cancer Research (325 citations). Michael Kauffman has collaborated with scholars based in United States, Canada and Denmark. Frequent co-authors include Julian Adams, Sharon Shacham, Thomas J. Kelly, Yosef Landesman, Dilara McCauley, Asfar S. Azmi, William Senapedis, Amro Aboukameel, David S. Siegel and Ramzi M. Mohammad. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer Research, Oncotarget and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.